Literature DB >> 24083951

Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis.

Laura A McCauley1, William Thomas, Theresa A Laguna, Warren E Regelmann, Antoinette Moran, Lynda E Polgreen.   

Abstract

RATIONALE: Recent literature suggests vitamin D has an effect on lung function and on the lung's ability to fight infection, both important in the cystic fibrosis (CF) population as predictors of morbidity and mortality.
OBJECTIVES: Our study assessed associations between vitamin D and % predicted lung function, pulmonary exacerbations, and first Pseudomonas aeruginosa infection in children with CF. We hypothesized that children with CF who have 25-hydroxy vitamin D (25-OHD) levels less than 30 μg/L would have lower % predicted lung function and more pulmonary exacerbations than those with 25-OHD greater than or equal to 30 μg/L.
METHODS: This retrospective longitudinal study of 130 children aged 6 to 18 years between 2000 and 2012 examined 25-OHD levels classed in three vitamin D groups: sufficient (≥30 μg/L), insufficient (20-29 μg/L), and deficient (<20 μg/L). Longitudinal models followed individuals' changing vitamin D groups over time to compare numbers of pulmonary exacerbations (defined by hospitalization), incidence of first P. aeruginosa infection, and % predicted lung function. Cross-sectional comparisons between vitamin D groups were performed at ages 8, 12, and 16 years.
MEASUREMENTS AND MAIN RESULTS: The prevalence of vitamin D deficiency and insufficiency increased slowly through adolescence. The rate of exacerbations for the deficient vitamin D group, aged 15 to 18 years, was 13.1 per 10 patient-years, significantly higher than 4.3 per 10 patient-years for the insufficient and sufficient vitamin D groups (P < 0.05), which were not significantly different There were no differences between vitamin D groups in pulmonary function or incidence of first P. aeruginosa infection, which was about 2 per 10 patient-years.
CONCLUSIONS: Higher 25-OHD levels in children with CF were associated with lower rates of pulmonary exacerbations and, in adolescents, higher FEV1.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24083951      PMCID: PMC3972970          DOI: 10.1513/AnnalsATS.201208-068OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  40 in total

1.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

2.  Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients.

Authors:  R K Lark; G E Lester; D A Ontjes; A D Blackwood; B W Hollis; M M Hensler; R M Aris
Journal:  Am J Clin Nutr       Date:  2001-03       Impact factor: 7.045

3.  An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation.

Authors:  V Tangpricha; A Kelly; A Stephenson; K Maguiness; J Enders; K A Robinson; B C Marshall; D Borowitz
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

4.  Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

Authors:  Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott
Journal:  Chest       Date:  2002-01       Impact factor: 9.410

5.  Improving rate of decline of FEV1 in young adults with cystic fibrosis.

Authors:  C Que; P Cullinan; D Geddes
Journal:  Thorax       Date:  2005-12-29       Impact factor: 9.139

6.  Vitamin d deficiency in cystic fibrosis.

Authors:  William B Hall; Amy A Sparks; Robert M Aris
Journal:  Int J Endocrinol       Date:  2010-01-28       Impact factor: 3.257

7.  Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis.

Authors:  Anne Stephenson; Michelle Brotherwood; Ronalee Robert; Eshetu Atenafu; Mary Corey; Elizabeth Tullis
Journal:  Am J Clin Nutr       Date:  2007-05       Impact factor: 7.045

8.  Vitamin D in infants with cystic fibrosis diagnosed by newborn screening.

Authors:  Liza A Neville; Sarath C Ranganathan
Journal:  J Paediatr Child Health       Date:  2009 Jan-Feb       Impact factor: 1.954

9.  Vitamin D deficiency in young children with severe acute lower respiratory infection.

Authors:  J Dayre McNally; Karen Leis; Loren A Matheson; Chandima Karuananyake; Koravangattu Sankaran; Alan M Rosenberg
Journal:  Pediatr Pulmonol       Date:  2009-10

10.  Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis.

Authors:  Sandra Asner; Valerie Waters; Melinda Solomon; Yvonne Yau; Susan E Richardson; Hartmut Grasemann; Farhad Gharabaghi; Dat Tran
Journal:  J Cyst Fibros       Date:  2012-05-10       Impact factor: 5.482

View more
  23 in total

1.  Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D3 administration.

Authors:  Jessica A Alvarez; Elizabeth Y Chong; Douglas I Walker; Joshua D Chandler; Ellen S Michalski; Ruth E Grossmann; Karan Uppal; Shuzhao Li; Jennifer K Frediani; Rabindra Tirouvanziam; ViLinh T Tran; Vin Tangpricha; Dean P Jones; Thomas R Ziegler
Journal:  Metabolism       Date:  2017-02-11       Impact factor: 8.694

Review 2.  Pancreatic Exocrine Insufficiency as a Complication of Gastrointestinal Surgery and the Impact of Pancreatic Enzyme Replacement Therapy.

Authors:  Adarsh Chaudhary; J Enrique Domínguez-Muñoz; Peter Layer; Markus M Lerch
Journal:  Dig Dis       Date:  2019-08-16       Impact factor: 2.404

3.  Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of DUSP1.

Authors:  N Dauletbaev; K Herscovitch; M Das; H Chen; J Bernier; E Matouk; J Bérubé; S Rousseau; L C Lands
Journal:  Br J Pharmacol       Date:  2015-10       Impact factor: 8.739

Review 4.  Role of vitamin D on gut microbiota in cystic fibrosis.

Authors:  Mansi Kanhere; Benoit Chassaing; Andrew T Gewirtz; Vin Tangpricha
Journal:  J Steroid Biochem Mol Biol       Date:  2016-11-03       Impact factor: 4.292

5.  Vitamin D Deficiency Does Not Result in a Breach of Host Defense in Murine Models of Pneumonia.

Authors:  Julia Niederstrasser; Christian Herr; Lisa Wolf; Claus M Lehr; Christoph Beisswenger; Robert Bals
Journal:  Infect Immun       Date:  2016-10-17       Impact factor: 3.441

6.  Vitamin D Deficiency and Critical Illness.

Authors:  Shailender Prasad; Dinesh Raj; Sumbul Warsi; Sona Chowdhary
Journal:  Indian J Pediatr       Date:  2015-05-14       Impact factor: 1.967

7.  Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial.

Authors:  Vin Tangpricha; Joshua Lukemire; Yuqing Chen; José Nilo G Binongo; Suzanne E Judd; Ellen S Michalski; Moon J Lee; Seth Walker; Thomas R Ziegler; Rabin Tirouvanziam; Susu M Zughaier; Supavit Chesdachai; Wendy A Hermes; James F Chmiel; Ruth E Grossmann; Amit Gaggar; Patricia M Joseph; Jessica A Alvarez
Journal:  Am J Clin Nutr       Date:  2019-03-01       Impact factor: 7.045

8.  Development and Evaluation of a Pharmacist-Driven Vitamin D Protocol for a Cystic Fibrosis Clinic.

Authors:  Elizabeth S Yett; Ha Phan; Alex R Mills; Joshua W Fleming; Joseph M Majure; Scott S Malinowski; Kim G Adcock
Journal:  J Pediatr Pharmacol Ther       Date:  2022-05-09

9.  Vitamins A, D, E status as related to supplementation and lung disease markers in young children with cystic fibrosis.

Authors:  HuiChuan J Lai; Lyanne H Chin; Sangita Murali; Taiya Bach; Danielle Sander; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2022-01-20

10.  Factors Contributing to Vitamin D Status at Hospital Admission for Pulmonary Exacerbation in Adults With Cystic Fibrosis.

Authors:  Anirudh Bhimavarapu; Qiao Deng; Marta Bean; Nick Lee; Thomas R Ziegler; Jessica Alvarez; Vin Tangpricha
Journal:  Am J Med Sci       Date:  2020-08-20       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.